Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone

Status Not yet recruiting

Clinical Trial Summary

Bone metastases appear in many cancers. They are associated with severe pain that is refractory to standard treatment. Improving the quality of life and better pain relief is therefore an essential goal of the treatment of metastatic disease. The most common site of long bone metastases is the superior femoral epiphysis.

The usual management of patients with bone metastases in the superior femoral epiphysis is based on gamma implant osteosynthesis when there is a known risk of fracture (Mirels score> 8). Nonetheless this surgery is only accessible to a few patients because of the associated morbidities.

Percutaneous cementoplasty has been developed to treat patients who are not eligible for conventional surgery. It consists in a filling of the bone cavity created by metastasis using an acrylic resin. However, these approaches do not completely prevent the risk of upper femoral epiphyseal fracture due to the low mechanical resistance of the resin to shear movements.

The Y-STRUT® implantable medical device was developed to overcome this risk of superior femoral epiphyseal fracture by the biomechanical strengthening of the proximal femur in addition to cementoplasty. It has been successfully tested in more than 70 patients with cancer but access to reimbursement and the APHP market have been postponed due to lack of sufficient clinical evidence.

The investigators propose this prospective phase 2a study in order to provide evidence of the performance of the Y-STRUT® implant.

Clinical Trial Description

The design consists in a multicenter national open simple arm trial.

All eligible patients with a lytic bone metastases of the superior femoral epiphysis will be included.

The main objective of this study is to describe the impact of the Y-STRUT® implant on the quality of life of patients with lytic bone metastases of the femoral neck by comparing quality of life scores before and one month after the intervention of implantation of the implant. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03887494
Study type	Interventional
Source	Assistance Publique - Hôpitaux de Paris
Contact	Olivier Pellerin, MD, PhD
Phone	+33156092660
Email	olivier.pellerin@aphp.fr
Status	Not yet recruiting
Phase	N/A
Start date	September 6, 2019
Completion date	June 30, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02507609` - Deep Neuromuscular Block on Cytokines Release and Postoperative Delirium	N/A
Completed	`NCT03906864` - Care Pathway for Sub-acute Hip Rehabilitation	N/A
Recruiting	`NCT04063891` - Vibration Therapy as an Intervention for Enhancing Trochanteric Hip Fracture Healing in Elderly Patients	N/A
Completed	`NCT05039879` - Life Improving Factors After a Hip Fracture
Terminated	`NCT03065101` - Trigen InterTAN vs Sliding Hip Screw RCT	N/A
Completed	`NCT03695081` - Patient Pathway Pharmacist - Optimal Drug-related Care	N/A
Completed	`NCT03545347` - Physiotherapy, Nutritional Supplement and Anabolic Steroids in Rehabilitation of Patients With Hip Fracture.	Phase 2
Recruiting	`NCT05971173` - Nutritional Optimization and Bone Health Management for Older Adults Undergoing Hip Fracture Surgery	Early Phase 1
Active, not recruiting	`NCT04957251` - Anterior vs Posterior Approach for Hip Hemiarthroplasty	N/A
Terminated	`NCT04372966` - Uncemented Versus Cemented Total Hip Arthroplasty for Displaced Intracapsular Hip Fractures	N/A
Withdrawn	`NCT05030688` - Fascia Iliaca Compartment Block and PENG Block for Hip Arthroplasty	N/A
Completed	`NCT04424186` - 'Rehabilitation for Life'	N/A
Not yet recruiting	`NCT04183075` - Impact of a Nutritional Supplement on the Recovery of the Nutritional Status of Patients With Spontaneous Hip Fracture	N/A
Withdrawn	`NCT05518279` - Early Administration Of Tranexamic Acid And Acute Blood Loss In Patients With Hip Fractures	Phase 3
Not yet recruiting	`NCT02892968` - ED Ultrasonographic Regional Anesthesia to Prevent Incident Delirium in Hip Fracture Patients	N/A
Not yet recruiting	`NCT02223572` - Secondary Fracture Prevention in Patients Who Suffered From Osteoporotic Fracture	N/A
Active, not recruiting	`NCT02247791` - Uncemented Compared to Cemented Femoral Stems in Total Hip Arthroplasty	N/A
Completed	`NCT00746876` - Unipolar or Bipolar Hemiarthroplasty in the Treatment of Displaced Femoral Neck Fractures.	N/A
Completed	`NCT00058864` - The HIP Impact Protection Program (HIP PRO)	N/A
Completed	`NCT05549011` - PENG vs SIFI Block for Positioning Pain During Spinal Anesthesia

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of the Impact of the Femoral Implant "Y-strut" on Lytic Bone Metastases of the Femoral Neck (WAZA-ARY) — WAZA-ARY

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms